Literature DB >> 7673990

Intramedullary non-Hodgkin's lymphoma of the spinal cord: a case report and literature review.

A C McDonald1, J A Nicoll, R Rampling.   

Abstract

We describe the case of a young man presenting with an extra-nodal, intramedullary non-Hodgkin's lymphoma of the cervical spinal cord. This is a very uncommon presentation of this neoplasm. The patient was treated with craniospinal radiotherapy, with survival for two and a half years before death from recurrent disease. A review of the relevant literature and recommendations for treatment of future cases are discussed.

Entities:  

Mesh：

Year:  1995        PMID： 7673990     DOI： 10.1007/bf01059959

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  20 in total

1.  Intramedullary non-Hodgkin's lymphoma of the spinal cord; a case report.

Authors:  M E Wong Chung; J P van Heesewijk; L M Ramos
Journal:  Eur J Radiol       Date:  1991 May-Jun       Impact factor: 3.528

2.  Primary malignant lymphomas of the central nervous system.

Authors:  J M Henry; R R Heffner; S H Dillard; K M Earle; R L Davis
Journal:  Cancer       Date:  1974-10       Impact factor: 6.860

3.  Pathology of primary reticulum cell sarcoma of the human central nervous system.

Authors:  M Reznik
Journal:  Acta Neuropathol Suppl       Date:  1975

4.  Primary spinal cord lymphoma: MR appearance.

Authors:  D A Bluemke; H Wang
Journal:  J Comput Assist Tomogr       Date:  1990 Sep-Oct       Impact factor: 1.826

5.  Intramedullary lymphoma of the spinal cord.

Authors:  R G Fisher
Journal:  Neurosurgery       Date:  1979-08       Impact factor: 4.654

6.  Combined modality therapy for primary CNS lymphoma.

Authors:  L M DeAngelis; J Yahalom; H T Thaler; U Kher
Journal:  J Clin Oncol       Date:  1992-04       Impact factor: 44.544

7.  Primary lymphoma of the spinal cord.

Authors:  U T Slager; R L Kaufman; K L Cohen; W J Tuddenham
Journal:  J Neuropathol Exp Neurol       Date:  1982-07       Impact factor: 3.685

8.  Increasing incidence of primary brain lymphoma in the US.

Authors:  N L Eby; S Grufferman; C M Flannelly; S C Schold; F S Vogel; P C Burger
Journal:  Cancer       Date:  1988-12-01       Impact factor: 6.860

9.  Malignant lymphoma of the central nervous system: a case of primary spinal intramedullary involvement.

Authors:  H Mitsumoto; A C Breuer; R J Lederman
Journal:  Cancer       Date:  1980-09-01       Impact factor: 6.860

10.  Syringomyelia affecting the entire spinal cord secondary to primary spinal intramedullary central nervous system lymphoma.

Authors:  I Landan; J Gilroy; D E Wolfe
Journal:  J Neurol Neurosurg Psychiatry       Date:  1987-11       Impact factor: 10.154
View more
  5 in total

1.  Hypophyseal non-Hodgkin's lymphoma presenting with diabetes insipidus: a case report.

Authors:  E M Merlo; A Maiolo; A Brocchieri; A Tua; G Grignani
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.130

Review 2.  Genetic basis of intramedullary spinal cord tumors and therapeutic implications.

Authors:  A T Parsa; A J Fiore; P C McCormick; J N Bruce
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

Review 3.  Intradural spinal tumors: current classification and MRI features.

Authors:  Kasim Abul-Kasim; Majda M Thurnher; Paul McKeever; Pia C Sundgren
Journal:  Neuroradiology       Date:  2007-12-15       Impact factor: 2.804

4.  Clinical reasoning: a 51-year-old man with cervical pain and progressively deteriorating gait.

Authors:  Dimitrios Rallis; Panagiotis Tsirigotis; Chryssa Arvaniti; Spiros Sgouros; Periclis G Foukas; Nikolaos Oikonomopoulos; Nikolaos Andronas; Ioannis G Panayiotides; Vasilios Kouloulias; Sotirios Papageorgiou; Konstantinos Voumvourakis; Eleftherios Stamboulis
Journal:  Neurology       Date:  2013-05-28       Impact factor: 9.910

5.  Primary intramedullary spinal cord lymphoma: a population-based study.

Authors:  Wuyang Yang; Tomas Garzon-Muvdi; Maria Braileanu; Jose L Porras; Justin M Caplan; Xiaoming Rong; Judy Huang; George I Jallo
Journal:  Neuro Oncol       Date:  2017-03-01       Impact factor: 12.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.